BE2014C053I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C053I2
BE2014C053I2 BE2014C053C BE2014C053C BE2014C053I2 BE 2014C053 I2 BE2014C053 I2 BE 2014C053I2 BE 2014C053 C BE2014C053 C BE 2014C053C BE 2014C053 C BE2014C053 C BE 2014C053C BE 2014C053 I2 BE2014C053 I2 BE 2014C053I2
Authority
BE
Belgium
Application number
BE2014C053C
Other languages
French (fr)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BE2014C053I2 publication Critical patent/BE2014C053I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BE2014C053C 2002-10-11 2014-09-09 BE2014C053I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11
PCT/JP2003/013070 WO2004033463A1 (ja) 2002-10-11 2003-10-10 ２，３−ジヒドロ−６−ニトロイミダゾ[２，１−ｂ]オキサゾール化合物

Publications (1)

Publication Number Publication Date
BE2014C053I2 true BE2014C053I2 (lt) 2022-08-30

Family

ID=32089299

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C053C BE2014C053I2 (lt) 2002-10-11 2014-09-09

Country Status (27)

Country Link
US (1) US7262212B2 (lt)
EP (2) EP1555267B1 (lt)
JP (1) JP4186065B2 (lt)
KR (1) KR100723847B1 (lt)
CN (4) CN101255170A (lt)
AR (4) AR041198A1 (lt)
AU (1) AU2003272979B2 (lt)
BE (1) BE2014C053I2 (lt)
BR (1) BRPI0314344B8 (lt)
CA (1) CA2497569C (lt)
CY (2) CY1113578T1 (lt)
DK (1) DK1555267T3 (lt)
ES (1) ES2400179T3 (lt)
FR (1) FR14C0066I2 (lt)
HK (2) HK1085463A1 (lt)
HU (1) HUS1400046I1 (lt)
LU (1) LU92517I2 (lt)
MX (1) MXPA05003674A (lt)
MY (1) MY139244A (lt)
PL (3) PL404913A1 (lt)
PT (1) PT1555267E (lt)
RU (1) RU2326121C3 (lt)
SI (1) SI1555267T1 (lt)
TW (1) TWI347946B (lt)
UA (1) UA83200C2 (lt)
WO (1) WO2004033463A1 (lt)
ZA (1) ZA200501033B (lt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
ES2526892T3 (es) * 2002-10-15 2015-01-16 Otsuka Pharmaceutical Co., Ltd. Método para preparar un compuesto 2-halo-4-nitroimidazol
BRPI0414909A (pt) 2003-10-31 2006-11-07 Otsuka Pharma Co Ltd composto, agente antituberculoso, e, método para produzir um composto
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
DK1731518T3 (da) 2004-03-31 2014-09-29 Nippon Soda Co Cyklisk aminsammensætning og skadedyrsbekæmpelsesmiddel
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
CA2609957A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
CA2610749C (en) * 2005-07-28 2013-06-04 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising 2,3-dihydro-6-nitroimidazo [2,1-b]oxazole derivatives
TW201434467A (zh) * 2005-10-05 2014-09-16 Otsuka Pharma Co Ltd 抗結核治療藥物及含彼之套組
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
KR101006363B1 (ko) 2005-10-06 2011-01-10 닛뽕소다 가부시키가이샤 가교 고리형 아민 화합물 및 유해 생물 방제제
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
US7750012B2 (en) 2005-12-21 2010-07-06 Decode Genetics Ehf Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
CA2640304A1 (en) * 2006-02-13 2007-08-23 Laboratoires Serono S.A. Sulfonamide derivatives for the treatment of bacterial infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
WO2008106128A2 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
AR070301A1 (es) * 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
AR067673A1 (es) * 2007-07-26 2009-10-21 Vitae Pharmaceuticals Inc Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
WO2009021965A2 (en) * 2007-08-15 2009-02-19 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
WO2009050204A1 (en) * 2007-10-16 2009-04-23 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
CA2715290A1 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009117109A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
JP5613656B2 (ja) * 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
NZ588954A (en) 2008-05-01 2012-08-31 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CN102119160B (zh) 2008-07-25 2014-11-05 贝林格尔·英格海姆国际有限公司 11β-羟基类固醇脱氢酶1的环状抑制剂
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
EP2323990B1 (en) * 2008-08-21 2014-06-18 Dynamit Nobel GmbH Explosivstoff- und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
ES2530266T3 (es) 2009-07-31 2015-02-27 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina y sus usos
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
IN2012DN01414A (lt) * 2009-07-31 2015-06-05 Global Alliance For Tb Drug Dev
WO2011052522A1 (ja) 2009-10-26 2011-05-05 富士フイルムＲｉファーマ株式会社 感染症診断薬
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
CN103596960B (zh) 2011-04-15 2016-11-16 大塚制药株式会社 6,7-二氢咪唑并[2,1-b][1,3]噁嗪杀菌剂
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
IN2013DE02954A (lt) * 2013-10-04 2015-04-10 Council Scient Ind Res
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
EP3209669B1 (en) * 2014-10-21 2018-11-07 Council of Scientific and Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
EP3252059A4 (en) * 2015-01-29 2018-07-11 Medshine Discovery Inc. Anti-pulmonary tuberculosis nitroimidazole derivative
EA201792154A1 (ru) * 2015-03-27 2018-02-28 Оцука Фармасьютикал Ко., Лтд. Способ получения 1-(4-гидроксифенил)-4-(4- трифторметоксифенокси)пиперидина или его соли
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
JP6905506B2 (ja) 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
US20190276475A1 (en) * 2016-07-22 2019-09-12 Medshine Discovery Inc. Crystal and salt of nitroimidazole, and manufacturing method thereof
SI3668879T1 (sl) * 2017-08-16 2022-04-29 Glaxosmithkline Intellectual Property Development Limited Nove spojine
SG11202011908YA (en) 2018-06-11 2020-12-30 Otsuka Pharma Co Ltd Delamanid-containing composition
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Also Published As

Publication number Publication date
UA83200C2 (en) 2008-06-25
CN101255170A (zh) 2008-09-03
CY1113578T1 (el) 2016-06-22
PL409525A1 (pl) 2014-11-10
LU92517I2 (fr) 2014-10-13
FR14C0066I2 (fr) 2015-05-22
RU2005114017A (ru) 2006-01-20
CN102532162B (zh) 2015-05-27
HK1085463A1 (en) 2006-08-25
ES2400179T3 (es) 2013-04-08
CA2497569A1 (en) 2004-04-22
CN101172981A (zh) 2008-05-07
HUS1400046I1 (hu) 2017-04-28
TWI347946B (en) 2011-09-01
KR100723847B1 (ko) 2007-05-31
US7262212B2 (en) 2007-08-28
AR086485A2 (es) 2013-12-18
DK1555267T3 (da) 2013-02-11
CY2014041I2 (el) 2016-07-27
AR091771A2 (es) 2015-02-25
AU2003272979A1 (en) 2004-05-04
EP1555267A4 (en) 2010-08-18
JP2004149527A (ja) 2004-05-27
BRPI0314344B8 (pt) 2021-05-25
ZA200501033B (en) 2006-06-28
FR14C0066I1 (lt) 2014-10-17
CN100366624C (zh) 2008-02-06
EP2570418A2 (en) 2013-03-20
PL217919B1 (pl) 2014-09-30
EP2570418A3 (en) 2013-07-03
PL376157A1 (en) 2005-12-27
CY2014041I1 (el) 2016-07-27
PT1555267E (pt) 2013-01-29
EP1555267B1 (en) 2013-01-16
MXPA05003674A (es) 2005-06-08
CN1705670A (zh) 2005-12-07
TW200420568A (en) 2004-10-16
EP1555267A1 (en) 2005-07-20
CN102532162A (zh) 2012-07-04
AR041198A1 (es) 2005-05-04
HK1171018A1 (en) 2013-03-15
WO2004033463A1 (ja) 2004-04-22
RU2326121C3 (ru) 2021-09-17
CA2497569C (en) 2011-05-24
SI1555267T1 (sl) 2013-05-31
AU2003272979B2 (en) 2009-07-23
AR089950A2 (es) 2014-10-01
JP4186065B2 (ja) 2008-11-26
RU2326121C2 (ru) 2008-06-10
MY139244A (en) 2009-09-30
KR20050061473A (ko) 2005-06-22
BR0314344A (pt) 2005-07-12
PL404913A1 (pl) 2013-09-30
BRPI0314344B1 (pt) 2019-11-26
US20060094767A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BE2019C547I2 (lt)
BE2019C510I2 (lt)
BE2018C021I2 (lt)
BE2017C049I2 (lt)
BE2017C005I2 (lt)
BE2016C069I2 (lt)
BE2016C040I2 (lt)
BE2016C013I2 (lt)
BE2018C018I2 (lt)
FR14C0066I1 (lt)
BE2014C051I2 (lt)
BE2014C041I2 (lt)
BE2014C030I2 (lt)
JP2003177869A5 (lt)
BRPI0302144B1 (lt)
BRPI0215435A2 (lt)
JP2003205916A5 (lt)
DE60228137D1 (lt)
JP2003205099A5 (lt)
JP2003248350A5 (lt)
JP2003052002A5 (lt)
ECSDI024326S (lt)
JP2003094179A5 (lt)
JP2003249461A5 (lt)
JP2003252950A5 (lt)